{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:21:13Z","timestamp":1773314473035,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammation"],"DOI":"10.1007\/s10753-026-02472-z","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:35:20Z","timestamp":1772091320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Paeoniflorin Alleviates Metabolic Dysfunction-Associated Steatotic Liver Disease by Inhibiting Hepatic Lipogenesis and Inflammation"],"prefix":"10.1007","volume":"49","author":[{"given":"Shi-zhang","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-feng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-ling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-feng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"1","key":"2472_CR1","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41467-023-36981-4","volume":"14","author":"B Tang","year":"2023","unstructured":"Tang, B., L. Tang, S. Li, S. Liu, J. He, P. Li, S. Wang, M. Yang, L. Zhang, Y. Lei, D. Tu, X. Tang, H. Hu, Q. Ouyang, X. Chen, and S. Yang. 2023. Gut microbiota alters host bile acid metabolism to contribute to intrahepatic cholestasis of pregnancy. Nature Communications 14(1):1305. https:\/\/doi.org\/10.1038\/s41467-023-36981-4","journal-title":"Nature Communications"},{"key":"2472_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","volume":"11","author":"T. Hardy","year":"2016","unstructured":"Hardy, T., F. Oakley, Q. M. Anstee, and C. P. Day. 2016. Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum. Annual Review of Pathology: Mechanisms of Disease 11:451\u2013496. https:\/\/doi.org\/10.1146\/annurev-pathol-012615-044224","journal-title":"Annual Review of Pathology: Mechanisms of Disease"},{"issue":"7","key":"2472_CR3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., B. A. Neuschwander-Tetri, M. Rinella, and A. J. Sanyal. 2018. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine 24(7):908\u2013922. https:\/\/doi.org\/10.1038\/s41591-018-0104-9","journal-title":"Nature Medicine"},{"issue":"1","key":"2472_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M., A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer. 2016. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"issue":"4","key":"2472_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou, F., J. Zhou, W. Wang, X. J. Zhang, Y. X. Ji, P. Zhang, Z. G. She, L. Zhu, J. Cai, and H. Li. 2019. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and Meta-Analysis. Hepatology 70(4):1119\u20131133. https:\/\/doi.org\/10.1002\/hep.30702","journal-title":"Hepatology"},{"key":"2472_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.metabol.2017.04.011","volume":"72","author":"I Reccia","year":"2017","unstructured":"Reccia, I., J. Kumar, C. Akladios, F. Virdis, M. Pai, N. Habib, and D. Spalding. 2017. Non-alcoholic fatty liver disease: A sign of systemic disease. Metabolism 72:94\u2013108. https:\/\/doi.org\/10.1016\/j.metabol.2017.04.011","journal-title":"Metabolism"},{"issue":"12","key":"2472_CR7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrendo.2016.124","volume":"12","author":"A Baiceanu","year":"2016","unstructured":"Baiceanu, A., P. Mesdom, M. Lagouge, and F. Foufelle. 2016. Endoplasmic reticulum proteostasis in hepatic steatosis. Nature Reviews. Endocrinology 12(12):710\u2013722. https:\/\/doi.org\/10.1038\/nrendo.2016.124","journal-title":"Nature Reviews. Endocrinology"},{"issue":"1","key":"2472_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2014.02.020","volume":"61","author":"E Munukka","year":"2014","unstructured":"Munukka, E., S. Pekkala, P. Wiklund, O. Rasool, R. Borra, L. Kong, X. Ojanen, S. M. Cheng, C. Roos, S. Tuomela, M. Alen, R. Lahesmaa, and S. Cheng. 2014. Gut-adipose tissue axis in hepatic fat accumulation in humans. Journal of Hepatology 61(1):132\u2013138. https:\/\/doi.org\/10.1016\/j.jhep.2014.02.020","journal-title":"Journal of Hepatology"},{"key":"2472_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.neuropharm.2017.01.009","volume":"116","author":"M Zheng","year":"2017","unstructured":"Zheng, M., C. Liu, Y. Fan, P. Yan, D. Shi, and Y. Zhang. 2017. Neuroprotection by Paeoniflorin in the MPTP mouse model of parkinson\u2019s disease. Neuropharmacology 116:412\u2013420. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.01.009","journal-title":"Neuropharmacology"},{"key":"2472_CR10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.biopha.2017.02.084","volume":"89","author":"HQ Zhou","year":"2017","unstructured":"Zhou, H. Q., W. Liu, J. Wang, Y. Q. Huang, P. Y. Li, Y. Zhu, J. B. Wang, X. Ma, R. S. Li, S. Z. Wei, K. Li, H. T. Li, J. Y. Li, X. H. Xiao, and Y. L. Zhao. 2017. Paeoniflorin attenuates ANIT-induced cholestasis by inhibiting apoptosis in vivo via mitochondria-dependent pathway. Biomedicine & Pharmacotherapy 89:696\u2013704. https:\/\/doi.org\/10.1016\/j.biopha.2017.02.084","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2472_CR11","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.biopha.2017.03.087","volume":"90","author":"Z Ma","year":"2017","unstructured":"Ma, Z., H. Liu, W. Wang, S. Guan, J. Yi, and L. Chu. 2017. Paeoniflorin suppresses lipid accumulation and alleviates insulin resistance by regulating the Rho kinase\/IRS-1 pathway in palmitate-induced HepG2Cells. Biomedicine & Pharmacotherapy 90:361\u2013367. https:\/\/doi.org\/10.1016\/j.biopha.2017.03.087","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"2472_CR12","doi-asserted-by":"publisher","first-page":"112800","DOI":"10.1016\/j.biopha.2022.112800","volume":"149","author":"X. Z. Wang","year":"2022","unstructured":"Wang, X. Z., L. Xia, X. Y. Zhang, Q. Chen, X. Li, Y. Mou, T. Wang, and Y. N. Zhang. 2022. The multifaceted mechanisms of Paeoniflorin in the treatment of tumors: State-of-the-Art. biomed Pharmacother 149:112800. https:\/\/doi.org\/10.1016\/j.biopha.2022.112800","journal-title":"biomed Pharmacother"},{"issue":"3","key":"2472_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/jpp\/rgaa042","volume":"73","author":"T Wang","year":"2021","unstructured":"Wang, T., X. Zhou, G. Kuang, R. Jiang, X. Guo, S. Wu, J. Wan, and L. Yin. 2021. Paeoniflorin modulates oxidative stress, inflammation and hepatic stellate cells activation to alleviate CCl4-induced hepatic fibrosis by upregulation of Heme oxygenase-1 in mice. Journal of Pharmacy and Pharmacology 73(3):338\u2013346. https:\/\/doi.org\/10.1093\/jpp\/rgaa042","journal-title":"Journal of Pharmacy and Pharmacology"},{"issue":"4","key":"2472_CR14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s12026-015-8773-7","volume":"64","author":"D Chen","year":"2016","unstructured":"Chen, D., Y. Li, X. Wang, K. Li, Y. Jing, J. He, Z. Qiang, J. Tong, K. Sun, W. Ding, Y. Kang, and G. Li. 2016. Generation of regulatory dendritic cells after treatment with Paeoniflorin. Immunologic Research 64(4):988\u20131000. https:\/\/doi.org\/10.1007\/s12026-015-8773-7","journal-title":"Immunologic Research"},{"key":"2472_CR15","doi-asserted-by":"publisher","unstructured":"Li, Y. C., J. Y. Qiao, B. Y. Wang, M. Bai, J. D. Shen, and Y. X. Cheng. 2018. Paeoniflorin ameliorates Fructose-Induced insulin resistance and hepatic steatosis by activating LKB1\/AMPK and AKT pathways. Nutrients 10(8). https:\/\/doi.org\/10.3390\/nu10081024","DOI":"10.3390\/nu10081024"},{"issue":"3","key":"2472_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ajps.2019.11.002","volume":"15","author":"C Wu","year":"2020","unstructured":"Wu, C., B. Li, Y. Zhang, T. Chen, C. Chen, W. Jiang, Q. Wang, and T. Chen. 2020. Intranasal delivery of Paeoniflorin nanocrystals for brain targeting. Asian Journal of Pharmaceutical Sciences 15(3):326\u2013335. https:\/\/doi.org\/10.1016\/j.ajps.2019.11.002","journal-title":"Asian Journal of Pharmaceutical Sciences"},{"key":"2472_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fphar.2019.00268","volume":"10","author":"JB Yu","year":"2019","unstructured":"Yu, J. B., Z. X. Zhao, R. Peng, L. B. Pan, J. Fu, S. R. Ma, P. Han, L. Cong, Z. W. Zhang, L. X. Sun, J. D. Jiang, and Y. Wang. 2019. Gut Microbiota-Based pharmacokinetics and the antidepressant mechanism of Paeoniflorin. Frontiers in Pharmacology 10:268. https:\/\/doi.org\/10.3389\/fphar.2019.00268","journal-title":"Frontiers in Pharmacology"},{"issue":"1","key":"2472_CR18","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","volume":"10","author":"C Caussy","year":"2019","unstructured":"Caussy, C., A. Tripathi, G. Humphrey, S. Bassirian, S. Singh, C. Faulkner, R. Bettencourt, E. Rizo, L. Richards, Z. Z. Xu, M. R. Downes, R. M. Evans, D. A. Brenner, C. B. Sirlin, R. Knight, and R. Loomba. 2019. A gut Microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nature Communications 10(1):1406. https:\/\/doi.org\/10.1038\/s41467-019-09455-9","journal-title":"Nature Communications"},{"issue":"3","key":"2472_CR19","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J. Boursier","year":"2016","unstructured":"Boursier, J., O. Mueller, M. Barret, M. Machado, L. Fizanne, F. Araujo-Perez, C. D. Guy, P. C. Seed, J. F. Rawls, L. A. David, G. Hunault, F. Oberti, P. Cales, and A. M. Diehl. 2016. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63(3):764\u2013775. https:\/\/doi.org\/10.1002\/hep.28356","journal-title":"Hepatology"},{"issue":"1","key":"2472_CR20","doi-asserted-by":"publisher","first-page":"e1004559","DOI":"10.1371\/journal.ppat.1004559","volume":"11","author":"J Boursier","year":"2015","unstructured":"Boursier, J., and A. M. Diehl. 2015. Implication of gut microbiota in nonalcoholic fatty liver disease. Plos Pathogens 11(1):e1004559. https:\/\/doi.org\/10.1371\/journal.ppat.1004559","journal-title":"Plos Pathogens"},{"issue":"4","key":"2472_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/19490976.2020.1712984","volume":"11","author":"NY Lee","year":"2020","unstructured":"Lee, N. Y., S. J. Yoon, D. H. Han, H. Gupta, G. S. Youn, M. J. Shin, Y. L. Ham, M. J. Kwak, B. Y. Kim, J. S. Yu, D. Y. Lee, T. S. Park, S. H. Park, B. K. Kim, H. C. Joung, I. S. Choi, J. T. Hong, D. J. Kim, S. H. Han, and K. T. Suk. 2020. Lactobacillus and pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut Microbiome. Gut Microbes 11(4):882\u2013899. https:\/\/doi.org\/10.1080\/19490976.2020.1712984","journal-title":"Gut Microbes"},{"issue":"7384","key":"2472_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nature10809","volume":"482","author":"J. Henao-Mejia","year":"2012","unstructured":"Henao-Mejia, J., E. Elinav, C. Jin, L. Hao, W. Z. Mehal, T. Strowig, C. A. Thaiss, A. L. Kau, S. C. Eisenbarth, M. J. Jurczak, J. P. Camporez, G. I. Shulman, J. I. Gordon, H. M. Hoffman, and R. A. Flavell. 2012. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482(7384):179\u2013185. https:\/\/doi.org\/10.1038\/nature10809","journal-title":"Nature"},{"key":"2472_CR23","doi-asserted-by":"publisher","unstructured":"Zhao, Z., Z. T. Deng, S. Huang, M. Ning, Y. Feng, Y. Shen, Q. S. Zhao, Y. Leng, and B. Alisol. 2022. Alleviates hepatocyte lipid accumulation and lipotoxicity via regulating RARalpha-PPARgamma-CD36 cascade and attenuates non-alcoholic steatohepatitis in mice. Nutrients 14(12). https:\/\/doi.org\/10.3390\/nu14122411","DOI":"10.3390\/nu14122411"},{"key":"2472_CR24","doi-asserted-by":"publisher","first-page":"665376","DOI":"10.3389\/fphar.2021.665376","volume":"12","author":"L Qu","year":"2021","unstructured":"Qu, L., X. Lin, C. Liu, C. Ke, Z. Zhou, K. Xu, G. Cao, and Y. Liu. 2021. Atractylodin attenuates dextran sulfate Sodium-Induced colitis by alleviating gut microbiota dysbiosis and inhibiting inflammatory response through the MAPK pathway. Frontiers in Pharmacology 12:665376. https:\/\/doi.org\/10.3389\/fphar.2021.665376","journal-title":"Frontiers in Pharmacology"},{"key":"2472_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.3389\/fmicb.2020.00731","volume":"11","author":"Z Sun","year":"2020","unstructured":"Sun, Z., J. Li, Y. Dai, W. Wang, R. Shi, Z. Wang, P. Ding, Q. Lu, H. Jiang, W. Pei, X. Zhao, Y. Guo, J. Liu, X. Tan, and T. Mao. 2020. Indigo naturalis alleviates dextran sulfate Sodium-Induced colitis in rats via altering gut microbiota. Frontiers in Microbiology 11:731. https:\/\/doi.org\/10.3389\/fmicb.2020.00731","journal-title":"Frontiers in Microbiology"},{"issue":"15","key":"2472_CR26","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1093\/nar\/gkaa615","volume":"48","author":"X Li","year":"2020","unstructured":"Li, X., J. Wang, X. Gong, M. Zhang, S. Kang, B. Shu, Z. Wei, Z. S. Huang, and D. Li. 2020. Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD\/NASH. Nucleic Acids Research 48(15):8255\u20138268. https:\/\/doi.org\/10.1093\/nar\/gkaa615","journal-title":"Nucleic Acids Research"},{"key":"2472_CR27","doi-asserted-by":"publisher","unstructured":"Tilg, H., S. Petta, N. Stefan, and G. Targher. 2025. Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.19615","DOI":"10.1001\/jama.2025.19615"},{"key":"2472_CR28","doi-asserted-by":"publisher","first-page":"CD009059","DOI":"10.1002\/14651858.CD009059.pub2","volume":"8","author":"ZL Liu","year":"2013","unstructured":"Liu, Z. L., L. Z. Xie, J. Zhu, G. Q. Li, S. J. Grant, and J. P. Liu. 2013. Herbal medicines for fatty liver diseases. Cochrane Database Systematic Review 8:CD009059. https:\/\/doi.org\/10.1002\/14651858.CD009059.pub2","journal-title":"Cochrane Database Systematic Review"},{"key":"2472_CR29","doi-asserted-by":"publisher","first-page":"121480","DOI":"10.1016\/j.ijpharm.2022.121480","volume":"615","author":"T Yuan","year":"2022","unstructured":"Yuan, T., S. Lv, W. Zhang, Y. Tang, H. Chang, Z. Hu, L. Fang, J. Du, S. Wu, X. Yang, Y. Guo, R. Guo, Z. Ge, L. Wang, C. Zhang, R. Wang, and W. Chen. 2022. PF-PLC micelles ameliorate cholestatic liver injury via regulating TLR4\/MyD88\/NF-kappaB and PXR\/CAR\/UGT1A1 signaling pathways in EE-induced rats. International Journal of Pharmaceutics 615:121480. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.121480","journal-title":"International Journal of Pharmaceutics"},{"issue":"12","key":"2472_CR30","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/s42255-022-00681-y","volume":"4","author":"HAB Paterson","year":"2022","unstructured":"Paterson, H. A. B., S. Yu, N. Artigas, M. A. Prado, N. Haberman, Y. F. Wang, A. M. Jobbins, E. Pahita, J. Mokochinski, Z. Hall, M. Guerin, J. A. Paulo, S. S. Ng, F. Villarroya, S. T. Rashid, W. Le Goff, B. Lenhard, I. Cebola, D. Finley, S. P. Gygi, C. R. Sibley, and S. Vernia. 2022. Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice. Nat Metab 4(12):1812\u20131829. https:\/\/doi.org\/10.1038\/s42255-022-00681-y","journal-title":"Nat Metab"},{"issue":"1","key":"2472_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41574-018-0096-z","volume":"15","author":"FJ Gonzalez","year":"2018","unstructured":"Gonzalez, F. J., C. Xie, and C. Jiang. 2018. The role of hypoxia-inducible factors in metabolic diseases. Nature Reviews. Endocrinology 15(1):21\u201332. https:\/\/doi.org\/10.1038\/s41574-018-0096-z","journal-title":"Nature Reviews. Endocrinology"},{"issue":"1","key":"2472_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","volume":"30","author":"AL Gomes","year":"2016","unstructured":"Gomes, A. L., A. Teijeiro, S. Buren, K. S. Tummala, M. Yilmaz, A. Waisman, J. P. Theurillat, C. Perna, and N. Djouder. 2016. Metabolic Inflammation-Associated IL-17A causes Non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell 30(1):161\u2013175. https:\/\/doi.org\/10.1016\/j.ccell.2016.05.020","journal-title":"Cancer Cell"},{"key":"2472_CR33","doi-asserted-by":"publisher","first-page":"153806","DOI":"10.1016\/j.phymed.2021.153806","volume":"93","author":"P. F. Hsieh","year":"2021","unstructured":"Hsieh, P. F., W. P. Jiang, P. Basavaraj, S. Y. Huang, P. Ruangsai, J. B. Wu, G. J. Huang, and W. C. Huang. 2021. Cell suspension culture extract of eriobotrya Japonica attenuates growth and induces apoptosis in prostate cancer cells via targeting SREBP-1\/FASN-driven metabolism and AR. Phytomedicine 93:153806. https:\/\/doi.org\/10.1016\/j.phymed.2021.153806","journal-title":"Phytomedicine"},{"issue":"6","key":"2472_CR34","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/iej.13468","volume":"54","author":"HW Wang","year":"2021","unstructured":"Wang, H. W., S. H. Kok, C. N. Yang, C. Y. Hong, C. W. Chi, M. H. Chen, S. J. Cheng, C. T. Shun, H. Yang, and S. K. Lin. 2021. Blockade of fatty acid signalling inhibits lipopolysaccharide-induced macrophage recruitment and progression of apical periodontitis. International Endodontic Journal 54(6):902\u2013915. https:\/\/doi.org\/10.1111\/iej.13468","journal-title":"International Endodontic Journal"},{"issue":"5","key":"2472_CR35","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1002\/hep.32045","volume":"74","author":"Y Hu","year":"2021","unstructured":"Hu, Y., W. He, Y. Huang, H. Xiang, J. Guo, Y. Che, X. Cheng, F. Hu, M. Hu, T. Ma, J. Yu, H. Tian, S. Tian, Y. X. Ji, P. Zhang, Z. G. She, X. J. Zhang, Z. Huang, J. Yang, and H. Li. 2021. Fatty acid Synthase-Suppressor screening identifies sorting nexin 8 as a therapeutic target for NAFLD. Hepatology 74(5):2508\u20132525. https:\/\/doi.org\/10.1002\/hep.32045","journal-title":"Hepatology"},{"key":"2472_CR36","doi-asserted-by":"publisher","unstructured":"Zhou, Y., Z. Li, M. Xu, D. Zhang, J. Ling, P. Yu, and Y. Shen. 2022. O-GlycNacylation remission retards the progression of Non-Alcoholic fatty liver Disease, cells. 11(22) https:\/\/doi.org\/10.3390\/cells11223637","DOI":"10.3390\/cells11223637"},{"issue":"4","key":"2472_CR37","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler, M., R. Schwabe, J. Hampe, P. Kubes, M. Heikenwalder, and F. Tacke. 2022. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits. Journal of Hepatology 77(4):1136\u20131160. https:\/\/doi.org\/10.1016\/j.jhep.2022.06.012","journal-title":"Journal of Hepatology"},{"key":"2472_CR38","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.nutres.2017.11.003","volume":"49","author":"S Houjeghani","year":"2018","unstructured":"Houjeghani, S., S. Kheirouri, E. Faraji, and M. A. Jafarabadi. 2018. l-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes: A double-blind placebo-controlled randomized clinical trial. Nutrition Research 49:96\u2013106. https:\/\/doi.org\/10.1016\/j.nutres.2017.11.003","journal-title":"Nutrition Research"},{"key":"2472_CR39","doi-asserted-by":"publisher","unstructured":"Schwank-Xu, C., E. Forsberg, M. Bentinger, A. Zhao, I. Ansurudeen, G. Dallner, S. B. Catrina, K. Brismar, and M. Tekle. 2021. L-Carnosine stimulation of coenzyme Q10 biosynthesis promotes improved mitochondrial function and decreases hepatic steatosis in diabetic conditions. Antioxidants (Basel) 10(5). https:\/\/doi.org\/10.3390\/antiox10050793","DOI":"10.3390\/antiox10050793"},{"key":"2472_CR40","doi-asserted-by":"publisher","unstructured":"Lee, S., T. O. Usman, J. Yamauchi, G. Chhetri, X. Wang, G. M. Coudriet, C. Zhu, J. Gao, R. McConnell, K. Krantz, D. Rajasundaram, S. Singh, J. Piganelli, A. Ostrowska, A. Soto-Gutierrez, S. P. Monga, A. D. Singhi, R. Muzumdar, A. Tsung, and H. H. Dong. 2022. Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis. Journal of Clinical Investigation 132(14). https:\/\/doi.org\/10.1172\/JCI154333","DOI":"10.1172\/JCI154333"},{"issue":"5","key":"2472_CR41","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41575-020-0269-9","volume":"17","author":"J Aron-Wisnewsky","year":"2020","unstructured":"Aron-Wisnewsky, J., C. Vigliotti, J. Witjes, P. Le, A. G. Holleboom, J. Verheij, M. Nieuwdorp, and K. Clement. 2020. Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders. Nature Reviews. Gastroenterology & Hepatology 17(5):279\u2013297. https:\/\/doi.org\/10.1038\/s41575-020-0269-9","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"issue":"7","key":"2472_CR42","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1053\/j.gastro.2022.01.058","volume":"162","author":"KC Bauer","year":"2022","unstructured":"Bauer, K. C., P. T. Littlejohn, V. Ayala, A. Creus-Cuadros, and B. B. Finlay. 2022. Nonalcoholic fatty liver disease and the Gut-Liver axis: Exploring an undernutrition perspective. Gastroenterology 162(7):1858\u20131875e2. https:\/\/doi.org\/10.1053\/j.gastro.2022.01.058","journal-title":"Gastroenterology"},{"issue":"2","key":"2472_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/gutjnl-2018-316307","volume":"68","author":"H Chu","year":"2019","unstructured":"Chu, H., Y. Duan, L. Yang, and B. Schnabl. 2019. Small metabolites, possible big changes: A microbiota-centered view of non-alcoholic fatty liver disease. Gut 68(2):359\u2013370. https:\/\/doi.org\/10.1136\/gutjnl-2018-316307","journal-title":"Gut"},{"issue":"8","key":"2472_CR44","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","volume":"76","author":"Z Safari","year":"2019","unstructured":"Safari, Z., and P. Gerard. 2019. The links between the gut Microbiome and non-alcoholic fatty liver disease (NAFLD). Cellular and Molecular Life Sciences 76(8):1541\u20131558. https:\/\/doi.org\/10.1007\/s00018-019-03011-w","journal-title":"Cellular and Molecular Life Sciences"},{"key":"2472_CR45","doi-asserted-by":"publisher","unstructured":"Kolodziejczyk, A. A., D. Zheng, O. Shibolet, and E. Elinav. 2019. The role of the Microbiome in NAFLD and NASH. Embo Molecular Medicine 11(2). https:\/\/doi.org\/10.15252\/emmm.201809302","DOI":"10.15252\/emmm.201809302"},{"issue":"10","key":"2472_CR46","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1111\/bph.15008","volume":"178","author":"X Hua","year":"2021","unstructured":"Hua, X., D. Y. Sun, W. J. Zhang, J. T. Fu, J. Tong, S. J. Sun, F. Y. Zeng, S. X. Ouyang, G. Y. Zhang, S. N. Wang, D. J. Li, C. Y. Miao, and P. Wang. 2021. P7C3-A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21\/FGF1, via the AMP-activated protein kinase\/CREB regulated transcription coactivator 2 pathway. British Journal of Pharmacology 178(10):2111\u20132130. https:\/\/doi.org\/10.1111\/bph.15008","journal-title":"British Journal of Pharmacology"},{"key":"2472_CR47","doi-asserted-by":"publisher","first-page":"9734560","DOI":"10.1155\/2020\/9734560","volume":"2020","author":"X Ding","year":"2020","unstructured":"Ding, X., T. Jian, J. Li, H. Lv, B. Tong, J. Li, X. Meng, B. Ren, and J. Chen. 2020. Chicoric acid ameliorates nonalcoholic fatty liver disease via the AMPK\/Nrf2\/NFkappaB signaling pathway and restores gut microbiota in High-Fat-Diet-Fed mice. Oxid Med Cell Longev 2020:9734560. https:\/\/doi.org\/10.1155\/2020\/9734560","journal-title":"Oxid Med Cell Longev"},{"issue":"26","key":"2472_CR48","doi-asserted-by":"publisher","first-page":"10050","DOI":"10.1021\/acs.jafc.3c01881","volume":"71","author":"K Feng","year":"2023","unstructured":"Feng, K., H. Zhang, C. Chen, C. T. Ho, M. Kang, S. Zhu, J. Xu, X. Deng, Q. Huang, and Y. Cao. 2023. Heptamethoxyflavone alleviates metabolic syndrome in High-Fat Diet-Fed mice by regulating the Composition, Function, and metabolism of gut microbiota. Journal of Agriculture and Food Chemistry 71(26):10050\u201310064. https:\/\/doi.org\/10.1021\/acs.jafc.3c01881","journal-title":"Journal of Agriculture and Food Chemistry"},{"issue":"9","key":"2472_CR49","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","volume":"22","author":"HC Lau","year":"2025","unstructured":"Lau, H. C., X. Zhang, and J. Yu. 2025. Gut Microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma. Nature Reviews. Gastroenterology & Hepatology 22(9):619\u2013638. https:\/\/doi.org\/10.1038\/s41575-025-01089-1","journal-title":"Nature Reviews. Gastroenterology & Hepatology"}],"container-title":["Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10753-026-02472-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-026-02472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10753-026-02472-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:01:58Z","timestamp":1773248518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10753-026-02472-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2472"],"URL":"https:\/\/doi.org\/10.1007\/s10753-026-02472-z","relation":{},"ISSN":["1573-2576"],"issn-type":[{"value":"1573-2576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}